NDA 022310 · Astrazeneca
Casodex
Bicalutamide · Oral
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 19, 2008 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Dec 19, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
220
64 Phase 3, 21 recruiting
FAERS reports
15,314
12,703 serious, 2,753 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2008 Original approval · Type 6 - New Indication (no longer used) · priority review ReviewLabelLetter
1 products under this application
- CASODEX · BICALUTAMIDE 50MG · TABLET, ORAL · Prescription · TE TBD
Clinical trials
Interventional ClinicalTrials.gov studies with "Bicalutamide" as an intervention, any sponsor and status, largest first.
- RADICALS - Radiotherapy and Androgen Deprivation In Combination After Local SurgeryPivotal-lookingCompleted
University College, LondonAcademic, hospital or other
NCT00541047 · 4,236 participants · Start Nov 2007 · Primary completion Jul 27, 2022
Drug: bicalutamide; goserelin acetate and 1 more · For: Gastrointestinal Complications; Prostate Cancer; Sexual Dysfunction and 1 more
Sites: Kelowna, Canada; Vancouver, Canada; London, Canada · 58 sites in all
- Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate CancerPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00657904 · 3,618 participants · Start Aug 1995 · Primary completion Jul 2008
Drug: Bicalutamide; Placebo · For: Non-metastatic Prostate Cancer
Sites: Birmingham, Alabama; Mobile, Alabama; Scottsdale, Arizona · 85 sites in all
- (Bicalutamide) Casodex vs Placebo in Non-metastatic Early Prostate CancerPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00673205 · 3,588 participants · Start Sep 1995 · Primary completion Aug 2008
Drug: Bicalutamide; Placebo · For: Non-Metastatic Prostate Cancer
Sites: Wooloongabba, Australia; East Melbourne, Australia; Graz, Austria · 128 sites in all
- SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate CancerPivotal-lookingCompleted
SWOG Cancer Research NetworkResearch network
NCT00002651 · 3,040 participants · Start May 1995 · Primary completion Jun 2013
Drug: bicalutamide; goserelin acetate · For: Prostate Cancer
Sites: Calgary, Canada; Edmonton, Canada; Vancouver, Canada · 14 sites in all
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Prostate Adenocarcinoma TransCutaneous HormonesPivotal-lookingStatus unknown
University College, LondonAcademic, hospital or other
NCT00303784 · 2,200 participants (planned) · Start Mar 2006 · Primary completion Aug 2021
Drug: Goserelin; Estradiol · For: Anemia; Cardiovascular Complications; Hot Flashes and 2 more
Sites: Burton-on-Trent, United Kingdom; Cambridge, United Kingdom; Coventry, United Kingdom · 32 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Prostate Radiation Therapy or Short-Term Androgen Deprivation Therapy and Pelvic Lymph Node Radiation Therapy With or Without Prostate Radiation Therapy in Treating Patients With a Rising Prostate Specific Antigen (PSA) After Surgery for Prostate CancerPivotal-lookingStatus unknown
Radiation Therapy Oncology GroupResearch network
NCT00567580 · 1,792 participants · Start Feb 2008 · Primary completion Jul 12, 2018
Drug: AA; LHRH agonist · For: Prostate Cancer
Sites: Birmingham, Alabama; Fairbanks, Alaska; Peoria, Arizona · 460 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- fatigue1,344
- death1,010
- prostatic specific antigen increased951
- asthenia819
- hot flush804
- prostate cancer757
- malignant neoplasm progression725
- drug ineffective613
- dizziness590
- nausea569
- dyspnoea553
- diarrhoea537
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 224 |
| 2005 | 268 |
| 2006 | 264 |
| 2007 | 235 |
| 2008 | 483 |
| 2009 | 606 |
| 2010 | 505 |
| 2011 | 469 |
| 2012 | 433 |
| 2013 | 560 |
| 2014 | 651 |
| 2015 | 884 |
| 2016 | 1,115 |
| 2017 | 1,170 |
| 2018 | 1,305 |
| 2019 | 1,011 |
| 2020 | 870 |
| 2021 | 890 |
| 2022 | 944 |
| 2023 | 693 |
| 2024 | 631 |
| 2025 | 735 |
| 2026 | 368 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Casodex (Bicalutamide)
2024 spending
$237K
Beneficiaries
17
50 claims
Per beneficiary
$13,961
$99.64 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $811,316 |
| 2021 | $650,583 |
| 2022 | $420,767 |
| 2023 | $381,414 |
| 2024 | $237,333 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran C, Ouk S, Clegg NJ, et al. · Science 2009 · Clinical Trial, Phase I, Clinical Trial, Phase II
- Injectable Therapy for Androgenetic Alopecia: A Systematic Review.
Beer J, Boghosian T, Mendez H, et al. · Dermatol Surg 2026 · Systematic Review
- Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Sweeney CJ, Martin AJ, Stockler MR, et al. · Lancet Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial.
Gu W, Han W, Luo H, et al. · Lancet Oncol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- Loss of SNAI2 in Prostate Cancer Correlates With Clinical Response to Androgen Deprivation Therapy.
Cmero M, Kurganovs NJ, Stuchbery R, et al. · JCO Precis Oncol 2021 · Clinical Trial, Phase II, Research Support, Non-U.S. Gov't
- Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.
Parker CC, Kynaston H, Cook AD, et al. · Lancet 2024 · Randomized Controlled Trial, Comparative Study
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.